Premal Thaker, MD, MS, discusses important implications and takeaways of the phase 1/2 OVATION study of IMMN-1 in addition to chemotherapy for the treatment of newly diagnosed epithelial ovarian ...

Targeted Oncology connects oncology professionals with updates on immunotherapy, biomarkers, cancer pathways, and targeted ...

Targeted Oncology connects oncology professionals with updates on immunotherapy, biomarkers, cancer pathways, and targeted ...

A study reveals significant genomic differences in metastatic prostate cancer among veterans, highlighting the need for ...

Combination therapy with savolitinib and osimertinib shows promising results in treating advanced NSCLC with EGFR mutations ...

Daratumumab effectively delays multiple myeloma relapse by monitoring minimal residual disease, offering hope for improved ...

During a live event, Priyanka Pophali, MD, MBBS, discussed CAR T-cell therapy caregiver challenges and referral ...

The IsKia trial reveals that isatuximab enhances MRD negativity in newly diagnosed multiple myeloma, especially in high-risk ...

Erika Hamilton, MD, discusses the mechanism of action of emiltatug ledadotin, a B7-H4-directed Dolasynthen antibody-drug conjugate.

During a live event, Neal E. Ready, MD, and participants discussed use of PD-L1 status in non–small cell lung cancer and ...

Targeted Oncology connects oncology professionals with updates on immunotherapy, biomarkers, cancer pathways, and targeted precision medicine strategies.

Alicia Morgans, MD, MPH, discusses new data that shows darolutamide with ADT significantly improves quality of life and delays pain for patients with metastatic hormone-sensitive prostate cancer.